INTRODUCTION
============

Middle East respiratory syndrome coronavirus (MERS-CoV) is a novel beta-coronavirus first identified in Saudi Arabia in 2012 ([@B1]). It causes severe acute respiratory infection, with a mortality rate of 36% ([@B2]). Most MERS-CoV infections occur in the Middle East, although travel-associated MERS cases have been reported in 17 countries outside the Middle East. As of November 3, 2016, 27 countries reported 1,813 laboratory-confirmed cases of infection with MERS-CoV, including 645 deaths, to the World Health Organization (WHO) ([@B2]).

In the Korean outbreak of MERS-CoV in 2015, the first known patient was a businessman returning from the Middle East. The outbreak was amplified by super-spreading events at hospitals and movement of patients between hospitals. Spreading events occurred until late June 2015, more than a month after the index patient was identified, resulting in a total of 186 patients with MERS-CoV infection and 38 fatalities, which is the largest outbreak outside the Arabian Peninsula ([@B3][@B4]). During the outbreak, almost 17,000 individuals at epidemiologic risk were quarantined, and all laboratory-confirmed cases were admitted to hospitals for isolation.

Of MERS-CoV cases, 44%--100% of individual outbreaks were linked to hospitals ([@B5][@B6]) and a nosocomial outbreak of MERS-CoV may result in a large cluster of cases, the so called "super-spreading events ([@B6][@B7])." However, it is not known whether the spreading events are attributable to host factors such as clinical manifestations or epidemiologic factors such as duration of the nonisolated period ([@B8]). To understand the transmission risk of MERS-CoV in healthcare settings, we assessed the clinical and epidemiologic characteristics of non-spreaders, spreaders, and super-spreaders during the Korean outbreak.

MATERIALS AND METHODS
=====================

Patients and data collection
----------------------------

All laboratory-confirmed cases were admitted to government-designated hospitals, regardless of the severity of their illness. They were discharged after the resolution of all clinical symptoms and when 2 consecutive daily sputum samples were negative for MERS-CoV by real-time reverse transcription polymerase chain reaction (rRT-PCR). Laboratory diagnoses were made according to the WHO guideline ([@B9]).

We reviewed the publically available epidemiologic database compiled by the Korea Centers for Disease Control and Prevention ([@B3]) and clinical database compiled by the Korean Society of Infectious Diseases (KSID) ([@B10]). Infectious disease specialists who had cared for MERS patients completed case record form which KSID developed. The clinical data included demographics, clinical features, and the results of the laboratory tests. Government daily reports and local Korean news reports on the MERS outbreak were also reviewed ([@B11]).

Definitions and subgroup analyses
---------------------------------

A spreader was defined as an index patient who was suspected of causing a secondary infection of MERS-CoV. Super-spreaders and usual-spreaders were defined as those who transmitted MERS-CoV to 6 or more and those who transmitted to fewer than 6 individuals, respectively. Nonisolated in-hospital days were defined as the sum of calendar days of the patient\'s hospital stay before being effectively isolated. Chest radiographs at presentation were analyzed and the number of abnormal lung zones, which were arbitrarily divided into 6 areas, was counted.

For subgroup analyses, we censored cases with symptom onset after June 7 after which stricter infection control measures were implemented by the government, such as public disclosure of the names of affected hospitals, organizing rapid response teams, and applying stronger surveillance and isolation policies ([@B12]). Healthcare workers were also censored in another subgroup analyses because many wore personal protective equipment, which could also confound the transmission risk.

Statistical analysis
--------------------

Multivariate analyses in a forward stepwise manner were performed with *P* = 0.050 as the threshold for entering and removing variables. For all analyses, a 2-tailed *P* value of 0.05 was considered significant. Statistical analyses were performed with PASW for Windows (version 18 software package; SPSS, Inc., Chicago, IL, USA).

Ethics statement
----------------

The Institutional Review Board at the Seoul National University Hospital approved the study. The board waived the requirement for written consent (IRB registration number 1607-062-775).

RESULTS
=======

Baseline characteristics
------------------------

Characteristics of 186 patients with laboratory-confirmed MERS-CoV infection are shown in [Table 1](#T1){ref-type="table"}. Of them, 15 patients (8.1%) transmitted MERS-CoV (the spreader group) to others, and 171 patients (91.9%) did not (the non-spreader group). Age, sex, and underlying diseases were not different between the 2 groups. Among the spreaders, 5 patients (33.3%) were super-spreaders, while 10 (66.7%) were usual-spreaders. Baseline characteristics of these 2 groups were not significantly different.

###### Comparison of patient demographics and clinical parameters between non-spreaders and spreaders, or usual-spreaders and super-spreaders during the 2015 Korean outbreak of MERS-CoV

![](jkms-32-744-i001)

  Characteristics                                                 Non-spreader (n = 171)   Spreader (n = 15)   *P* value                      
  --------------------------------------------------------------- ------------------------ ------------------- ------------------- ---------- -------
  Patient characteristics                                                                                                                     
   Age, mean (± SD)                                               54.4 (± 16.2)            54.4 (± 18.0)       50.6 (± 19.3)       0.780      0.689
   Male                                                           99 (57.9)                8 (80.0)            4 (80.0)            0.108      1.000
   Underlying diseases                                                                                                                        
    DM                                                            33 (19.3)                0 (0.0)             1 (20.0)            0.251      1.000
    Hypertension                                                  51 (29.8)                3 (30.0)            1 (20.0)            0.797      0.682
    Chronic kidney diseases                                       8 (4.7)                  1 (10.0)            0 (0.0)             0.732      1.000
    Chronic heart diseases                                        15 (8.8)                 0 (0.0)             0 (0.0)             0.999      NA
    Chronic lung diseases                                         17 (9.9)                 2 (20.0)            0 (0.0)             0.679      0.999
    Chronic liver diseases                                        9 (5.3)                  1 (10.0)            0 (0.0)             0.818      1.000
  Clinical characteristics at presentation                                                                                                    
   Signs and symptoms^\*^                                                                                                                     
    Fever (≥ 38.5℃)                                               22 (13.0)                5 (50.0)            1 (20.0)            0.009      0.280
    Systolic BP ≤ 90 mmHg                                         9 (5.3)                  2 (20.0)            0 (0.0)             0.227      0.999
    Diastolic BP ≤ 60 mmHg                                        28 (16.6)                3 (30.0)            1 (20.0)            0.329      0.682
    Respiratory rate \> 24/min                                    21 (12.4)                5 (50.0)            0 (0.0)             0.034      0.999
    Cough                                                         93 (55.0)                9 (90.0)            4 (80.0)            0.031      0.598
    Sputum                                                        63 (37.3)                9 (90.0)            2 (40.0)            0.011      0.062
    Dyspnea                                                       32 (18.9)                6 (60.0)            3 (60.0)            0.001      1.000
    Myalgia                                                       71 (42.0)                5 (50.0)            3 (60.0)            0.399      0.715
    Headache                                                      34 (20.1)                1 (10.0)            2 (40.0)            0.991      0.199
    Diarrhea                                                      32 (18.9)                1 (10.0)            2 (40.0)            0.920      0.199
   Laboratory tests                                                                                                                           
    WBC \> 10,000 /μL or \< 4,000 /μL^†^                          75 (46.6)                4 (40.0)            4 (80.0)            0.617      0.165
    Platelet \< 100,000 /μL^†^                                    28 (17.4)                3 (30.0)            2 (40.0)            0.140      0.699
    CRP ≥ 3.0 mg/dL^‡^                                            66 (43.4)                8 (88.9)            4 (80.0)            0.008      0.653
    BUN \> 20 mg/dL^§^                                            24 (15.4)                4 (40.0)            0 (0.0)             0.267      0.999
    Creatinine \> 1.5 mg/dL^§^                                    8 (5.1)                  1 (10.0)            0 (0.0)             0.799      1.000
   CXR abnormality in more than 3 lung zones^∥^                   17 (10.3)                5 (50.0)            2 (40.0)            \< 0.001   0.715
  Symptom onset to negative conversion, day, median (IQR)^¶^      17.0 (13.0--21.0)        23.5 (17.8--28.3)   32.0 (28.3--43.3)   \< 0.001   0.129
  Clinical outcomes                                                                                                                           
   Mechanical ventilation^\*^                                     36 (21.3)                7 (70.0)            2 (40.0)            0.002      0.274
   Days from symptom onset to mechanical ventilation, (IQR)^\*^   10.0 (7.0--12.0)         6.5 (5.5--8.8)      10.5 (9.0--12.0)    0.221      0.159
   Mortality                                                      31 (18.1)                4 (40.0)            1 (20.0)            0.162      0.447
   Days from symptom onset to death, median (IQR)                 15.0 (12.0--21.0)        9.0 (3.8--9.0)      5.0 (5.0--5.0)      0.032      0.504

Data shown are number (%) not otherwise specified.

MERS-CoV = Middle East Respiratory Syndrome Coronavirus, SD = standard deviation, DM = diabetes mellitus, NA = not available, BP = blood pressure, WBC = white blood cell, CRP = C-reactive protein, BUN = blood urea nitrogen, CXR = chest X-ray, IQR = interquartile range.

^\*^Data were unavailable in 2 cases (1.1%); ^†^Data were unavailable in 10 cases (5.4%); ^‡^Data were unavailable in 20 cases (10.8%); ^§^Data were unavailable in 15 cases (8.1%); ^∥^Data were unavailable in 6 cases (3.2%); ^¶^Data were unavailable in 43 cases (23.1%).

Clinical characteristics
------------------------

At presentation, patients in the spreader group were more likely than those in the non-spreader group to have a fever of ≥ 38.5°C (40.0% vs. 13.0%, *P* = 0.009) and a tachypnea of \> 24 breaths per minute (33.3% vs. 12.4%, *P* = 0.034). They were also more likely to have lower respiratory manifestations such as cough, sputum, and dyspnea (86.7% vs. 55.0%, *P* = 0.031; 73.3% vs. 37.3%, *P* = 0.011; and 60.0% vs. 18.9%, *P* = 0.001, respectively).

On admission, elevated C-reactive protein (≥ 3.0 mg/dL) was the only laboratory parameter that was more common in the spreader than the non-spreader group (85.7% vs. 43.4%, *P* = 0.008). Infiltrates involving 3 or more lung zones on chest radiographs taken at presentation were more common in the spreader group than in the non-spreader group (46.7% vs. 10.3%, *P* \< 0.001). The median days from the onset of illness to the negative conversion of sputum MERS-CoV by rRT-PCR were significantly different (27.0 vs. 17.0 days, *P* \< 0.001).

Treatment with mechanical ventilation was required in 21.3% (36/169) of the non-spreader group and 60.0% (9/15) of the spreader group (*P* = 0.002). Deaths occurred in 18.1% (31/171) of the non-spreader group and 33.3% (5/15) of the spreader group (*P* = 0.162). Median days from symptom onset to death was significantly different (15.0 vs. 9.0 days, *P* = 0.032). Clinical parameters were not different between super-spreaders and usual-spreaders.

Epidemiologic characteristics
-----------------------------

The course of disease spread could not be determined in 10 patients, including 5 with an unidentified source of infection and 5 with more than one possible scenario. Excluding the first imported case, the courses of disease spread could be determined in 175 patients. Of them, 173 were infected at healthcare facilities (12 hospitals, 3 clinics, and 2 ambulances). The disease was transmitted to 2 remaining patients in household settings. The date of symptom onset could not be determined in 5 patients, including 2 patients who were asymptomatic and 3 with an ambiguous onset of MERS-CoV symptoms during another illness.

Of the 15 spreaders, 5 and 8 cases were in the second- and third-chain of transmission, respectively ([Table 2](#T2){ref-type="table"}). Spreaders transmitted MERS-CoV from days 1 to 11 of their illness (median, 7 days; interquartile range \[IQR\], 5 to 8 days) ([Fig. 1A](#F1){ref-type="fig"}). The number of patients infected by each spreader ranged from 1 to 84 (IQR, 1 to 12).

###### Comparison of epidemiologic characteristics between non-spreaders and spreaders, or usual-spreaders and super-spreaders during the 2015 Korean outbreak of MERS-CoV
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  Epidemiologic characteristics                       Non-spreader (n = 171)   Spreader (n = 15)   *P* value                   
  --------------------------------------------------- ------------------------ ------------------- ---------------- ---------- -------
  Phase in chain of transmission                                                                                    0.003      0.058
   Primary                                            0 (0.0)                  0 (0.0)             1 (20.0)                    
   Secondary                                          25 (14.6)                2 (22.2)            3 (60.0)                    
   Tertiary                                           116 (67.8)               7 (77.8)            1 (20.0)                    
   Quaternary                                         23 (13.5)                0 (0.0)             0 (0.0)                     
   Undetermined                                       7 (4.1)                  1 (10.0)            0 (0.0)                     
  Symptom onset after June 7^\*^                      48 (28.9)                3 (30.0)            0 (0.0)          0.466      0.999
  Median incubation period, day, mean (± SD)^†^       7.4 (± 4.5)              7.8 (± 2.6)         8.0 (± 5.0)      0.716      0.905
  Symptom onset to isolation, day, median (IQR)^\*^   2.0 (1.0--6.0)           5.0 (3.8--5.8)      8.0 (4.0--9.0)   0.057      0.267
  Nonisolated in-hospital days, median (IQR)          0.0 (0.0--2.0)           2.0 (0.8--4.5)      7.0 (4.0--9.0)   \< 0.001   0.061
  Nonisolated in-hospital days ≥ 2 day                54 (31.6)                6 (60.0)            5 (100.0)        0.003      0.999
  Symptom onset to diagnosis, day, mean (± SD)^\*^    6.5 (± 3.9)              7.5 (± 2.6)         8.8 (± 3.4)      0.178      0.400

Data shown are number (%) not otherwise specified.

MERS-CoV = Middle East Respiratory Syndrome Coronavirus, SD = standard deviation, IQR = interquartile range.

^\*^Data were unavailable in 5 cases (2.7%); ^†^Data were unavailable in 7 cases (3.8%).

![Epidemiologic characteristics of 2015 Korean MERS-CoV outbreak. (**A**) Cumulative number of infected patients according to day of illness of each spreader. When infected patients were exposed to a spreader for more than one day, the number of infected patients was equally divided by the duration (day) of exposure. Different colors denote infections transmitted by different spreaders. Note that the 5 super-spreaders transmitted the virus to 92% (161/175) of all cases. (**B**) Nonisolated in-hospital days according to the date of symptom onset of each patient. Two spreaders transmitted MERS-CoV to healthcare workers despite the fact that they had been isolated before their symptom onset. (**C**) Days from symptom onset to diagnosis according to the date of symptom onset of each patient.\
MERS-CoV = Middle East Respiratory Syndrome Coronavirus.](jkms-32-744-g001){#F1}

The median duration of incubation was not different between the spreader and non-spreader groups. Median nonisolated in-hospital days were 4 and 0 days in the spreader and non-spreader groups, respectively (IQR, 1 to 7 vs. 0 to 2 days, *P* \< 0.001).

Nonisolated in-hospital days were significantly different among the non-spreader, usual-spreader, and super-spreader groups ([Fig. 2A](#F2){ref-type="fig"}). Nonisolated in-hospital days of spreaders were also positively associated with the total number of infected patients, and the number of infected patients per spreader (R^2^ = 0.520 and 0.625; *P* = 0.068 and 0.034, respectively) ([Fig. 2B](#F2){ref-type="fig"}).

![Contribution of nonisolated in-hospital days to spreading events. (**A**) Nonisolated in-hospital days in non-spreader, usual-spreader, and super-spreader groups. Dashed lines denote median values at each group. Data points at 0 are shown at different level for clarity. (**B**) Number of spreaders (S) and infected patients (I), and I/S ratio according to nonisolated in-hospital days of spreaders. There were positive correlation between nonisolated in-hospital days of spreaders and I (red broken line) or I/S ratio (green broken line).](jkms-32-744-g002){#F2}

Epidemiologic characteristics of super-spreaders and usual-spreaders were not different. However, nonisolated in-hospital days tended to be higher in the super-spreader group (median, 2.0 vs. 7.0 days, *P* = 0.061). The median number of nonisolated in-hospital days was 1 day in patients who developed symptoms before June 7 and 0 days in patients who developed symptoms after that date (IQR, 0 to 3 vs. 0 to 1 day, *P* = 0.001) ([Fig. 1B](#F1){ref-type="fig"}, [Supplementary Table 1](#S1){ref-type="supplementary-material"}). Days from symptom onset to diagnosis were also significantly different between these groups (mean, 7.5 vs. 4.6, *P* \< 0.001) ([Fig. 1C](#F1){ref-type="fig"}, [Supplementary Table 1](#S1){ref-type="supplementary-material"}).

Risk factors for transmission
-----------------------------

In multivariate analysis, fever (≥ 38.5°C) (adjusted odds ratio \[aOR\], 5.54; 95% confidence interval \[CI\], 1.38--22.30; *P* = 0.016), chest infiltrates in more than 3 lung zones (aOR, 7.33; 95% CI, 1.93--27.79; *P* = 0.003), and a longer nonisolated in-hospital day (aOR, 1.32 per 1 day; 95% CI, 1.09--1.60; *P* = 0.004) were independently associated with the spreader group vs. the non-spreader group ([Table 3](#T3){ref-type="table"}). Further inclusion of other variables did not result in additional significance.

###### Forward stepwise multivariate analysis for risk factors for transmission of MERS-CoV

![](jkms-32-744-i003)

  Variables                                    Non-spreader (n = 171)   Spreader (n = 15)   aOR (95% CI)         *P* value
  -------------------------------------------- ------------------------ ------------------- -------------------- -----------
  Fever (≥ 38.5℃)                              22 (13.0)                6 (40.0)            5.54 (1.38--22.30)   0.016
  CXR abnormality in more than 3 lung zones    17 (10.3)                7 (46.7)            7.33 (1.93--27.79)   0.003
  Nonisolated in-hospital days, median (IQR)   0.0 (0.0--2.0)           4.0 (1.0--7.0)      1.32 (1.09--1.60)    0.004

Data shown are number (%).

MERS-CoV = Middle East Respiratory Syndrome Coronavirus, aOR = adjusted odds ratio, CI = confidence interval, CXR = chest X-ray, IQR = interquartile range.

When we censored the data on symptom onset after June 7 or unknown onset (n = 56), dyspnea (aOR, 4.38; 95% CI, 1.13--16.90; *P* = 0.032), and a more nonisolated in-hospital days (aOR, 1.31 per 1 day; 95% CI, 1.07--1.60; *P* = 0.009) were associated with the spreader group ([Supplementary Tables 2](#S2){ref-type="supplementary-material"} and [3](#S3){ref-type="supplementary-material"}).

When healthcare workers were censored (n = 39), chest X-ray abnormalities in more than 3 lung zones (aOR, 4.97; 95% CI, 1.28--19.35; *P* = 0.021), and a more nonisolated in-hospital days (aOR, 5.63 per 1 day; 95% CI, 1.10--28.75; *P* = 0.038) were associated with the spreader groups ([Supplementary Tables 4](#S4){ref-type="supplementary-material"} and [5](#S5){ref-type="supplementary-material"}).

DISCUSSION
==========

Hospital outbreaks were the defining characteristic of the Korean MERS-CoV outbreak in 2015. In this study, spreaders more frequently had high fever, more extensive infiltrates on chest radiographs, and a longer time to negative conversion of MERS-CoV rRT-PCR than non-spreaders, all suggesting more severe pneumonia. The spreader group had a significantly longer duration of nonisolated in-hospital days than the non-spreader groups.

Clinical parameters did not differ between super-spreaders and usual-spreaders, whereas nonisolated in-hospital days were substantially different between these 2 groups. These data suggest that large hospital outbreaks or super-spreading events may not be attributable to clinical manifestations, but to delay in isolation.

Spreaders transmitted MERS-CoV between days 1 and 11 of their illness. Of note, even a 1- or 2-day delay in isolating patients led secondary infections, with a peak of cumulative number on the seventh day of illness. These findings imply that MERS-CoV could be transmitted frequently during the early course of the disease. A recent virus shedding study showed that MERS-CoV titers in sputum samples were around 10^8^ copies per milliliter as early as 3 days after symptom onset, while the viral shedding kinetics of the SARS-CoV infection was an inverted V shape, with its sharp peak around day 10 ([@B13]). These findings suggest that control of a MERS-CoV outbreak would be more difficult than that of a SARS-CoV outbreak. Considering that the shortest incubation period of MERS-CoV infection is 2 days and that patients may transmit the disease with a high viral load even in the early course of their illness, early detection and isolation of patients is imperative to control an outbreak of MERS-CoV.

A standard approach to control an outbreak begins with identifying all exposed individuals and assessing them for close contact, followed by quarantine. However, this approach is labor-intensive and time-consuming, especially when many individuals are exposed. Moreover, identification of all exposed individuals is difficult, because many, such as visitors and family members, may not be registered with hospitals. Indeed, 43.2% of the patients in Korea during the 2015 outbreak had not been identified as exposed individuals and were not monitored ([@B14]). Our experience suggests that quarantining all exposed individuals first, followed by an assessment of and monitoring of their close contacts may shorten the delay in isolating MERS patients, especially in healthcare settings.

Days of nonisolated in-hospital stay and symptom onset to diagnosis were significantly longer in patients who developed symptoms before June 7 than in patients who did after that date. The last super-spreader developed symptoms on June 5, and no additional super-spreading events occurred after June 7. All advocate the necessity of early adoption of an aggressive isolation policy.

Since this was an analysis of a single outbreak, it should be interpreted with caution. Additionally, although we analyzed the severity of symptom or chest infiltrations and time to negative conversion of MERS-CoV rRT-PCR, lack of each patient\'s serial viral load titers limited a direct evaluation of the degree of viral shedding, which could be another limitation.

In conclusion, high fever, more extensive chest infiltrates, and delay in isolation were associated with the transmission of MERS-CoV. Nonisolated in-hospital days were the only parameter that tended to be associated with super-spreaders compared with usual-spreaders. Early active quarantine might help control a future outbreak of MERS.
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